跳至主要内容
临床试验/NCT07128992
NCT07128992尚未招募不适用

The Impact of Need-driven Treatment of Insulin-Deficient Diabetes on the Care Events, Glycemic Control, Risk Factors, and Complications in the Pirkanmaa Wellbeing Services County, Finland

Tampere University Hospital0 个研究点目标入组 125 人开始时间: 2025年10月6日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
125
主要终点
Percentage of patients in good glycemic control

研究概览

简要总结

This prospective study evaluates the safety of extending the interval of routine calendar-based follow-up visits from every 12 months to every 24 months in patients with type 1 diabetes who are in good glycemic control and suitable for remote monitoring. The primary outcome is the proportion of patients who maintain good glycemic control during the 24-month follow-up period.

Participants will attend two in-person visits at baseline (month 0) and at the end of follow-up (month 24), which include a comprehensive clinical examination, assessment of glucose control, and laboratory testing. One remote contact will occur at month 12 for prescription renewal and review of glucose data. Patients may contact their care unit as needed throughout the study. At the baseline and final visits, participants will complete a questionnaire assessing their perceived ability to manage self-care, the safety of the care plan, and their ability to contact their care provider when necessary.

详细描述

The primary outcome of this study is the proportion of patients who maintain good glycemic control during the 24-month follow-up period. A clinically significant result is defined as no more than 14% of patients (95% confidence interval: 8%-20%) experiencing deterioration in glucose control, indicated by Time in Range (TIR) < 70% or HbA1c > 53 mmol/mol. If at least 125 patients are enrolled, need-based care can be demonstrated to be safe.

The study also evaluates the performance and safety of the "MD Diabetes Huolijono" software application, which issues alerts to healthcare professionals if glucose control worsens or if the patient is hospitalized. Between visits, patients using a Libre sensor with multiple daily insulin injections will be monitored using the MD Diabetes Huolijono system, while other patients will continue standard self-monitoring.

Healthcare contact data will be retrieved from the data service for each participant for the 24 months prior to study enrollment and throughout the follow-up period.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Diagnosis of type 1 diabetes
  • Treatment with multiple daily injections or insulin pump therapy
  • Duration of diabetes ≥ 1 year
  • Good glycemic control over the previous two weeks, defined as:
  • HbA1c < 53 mmol/mol
  • Time in Range (TIR) > 70%
  • Time Below Range (TBR) < 4%
  • Time Above Range (TAR) < 25%
  • Use of a continuous glucose monitoring system connected via a smartphone application
  • Under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)
  • Willing to accept remote diabetes care by granting the diabetes team at Tampere University Hospital access to glucose data
  • No need for regular specialist care due to other medical conditions
  • Provides informed consent to participate in the study

排除标准

  • Age < 18 years
  • Duration of diabetes < 1 year
  • Pregnancy
  • Not using multiple daily injections or insulin pump therapy
  • Not using a continuous glucose monitoring system
  • Does not accept remote care
  • History of diabetic ketoacidosis or severe hypoglycemia within the past 12 months
  • Presence of retinopathy
  • No retinal imaging performed within the past 12 months
  • Urine albumin-creatinine ratio (uACR) > 3 mg/mmol or estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² on two occasions over a period of more than 3 months
  • Undergoing dialysis or post-kidney transplantation
  • Cardiovascular disease (excluding hypertension)
  • Neuropathy, foot ulcer, or amputation (foot risk category 1-3)
  • Scheduled hospital outpatient visits for other specialties within the next 12 months
  • Not under specialist diabetes care within the Pirkanmaa Wellbeing Services County (Pirha)

结局指标

主要结局

Percentage of patients in good glycemic control

时间窗: At the baseline and at 24 months of follow-up

Percentage of patients with TIR \> 70%, GMI \< 53 mmol/mol, and HbA1c \< 53 mmol/mol

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Saara Metso

Head of the unit of endocrinology, Associate professor

Tampere University Hospital

相似试验